- Home
- KALV vs GDEN Comparison
KALV vs GDEN Comparison
Compare KALV & GDEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- GDEN
- Stock Information
- Founded
- KALV N/A
- GDEN 1998
- Country
- KALV United States
- GDEN United States
- Employees
- KALV N/A
- GDEN N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- GDEN Services-Misc. Amusement & Recreation
- Sector
- KALV Health Care
- GDEN Consumer Discretionary
- Exchange
- KALV Nasdaq
- GDEN Nasdaq
- Market Cap
- KALV 637.9M
- GDEN 727.9M
- IPO Year
- KALV N/A
- GDEN 1999
- Fundamental
- Price
- KALV $15.82
- GDEN $24.80
- Analyst Decision
- KALV Strong Buy
- GDEN Buy
- Analyst Count
- KALV 9
- GDEN 7
- Target Price
- KALV $26.29
- GDEN $34.86
- AVG Volume (30 Days)
- KALV 734.1K
- GDEN 224.9K
- Earning Date
- KALV 09-09-2025
- GDEN 11-06-2025
- Dividend Yield
- KALV N/A
- GDEN 4.03%
- EPS Growth
- KALV N/A
- GDEN N/A
- EPS
- KALV N/A
- GDEN 0.54
- Revenue
- KALV N/A
- GDEN $649,900,000.00
- Revenue This Year
- KALV N/A
- GDEN N/A
- Revenue Next Year
- KALV $221.95
- GDEN $2.29
- P/E Ratio
- KALV N/A
- GDEN $45.84
- Revenue Growth
- KALV N/A
- GDEN N/A
- 52 Week Low
- KALV $7.30
- GDEN $22.66
- 52 Week High
- KALV $16.32
- GDEN $35.49
- Technical
- Relative Strength Index (RSI)
- KALV 71.16
- GDEN 40.85
- Support Level
- KALV $13.72
- GDEN $23.95
- Resistance Level
- KALV $13.96
- GDEN $25.49
- Average True Range (ATR)
- KALV 0.69
- GDEN 0.60
- MACD
- KALV 0.31
- GDEN 0.11
- Stochastic Oscillator
- KALV 99.15
- GDEN 45.45
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.